What Is Zofran?
Zofran is a drug designed by GlaxoSmithKline (GSK), to be used to prevent nausea and vomiting (NVM) which is caused by cancer chemotherapy, radiation therapy and surgery. Zofran is in a category of medications called 5-HT3 receptor antagonists and works by blocking serotonin. Serotonin is a natural substance that may cause nausea and vomiting.
When Zofran was authorized for use in 1991 by the Food and Drug Administration (FDA), it was authorized for use for the above conditions only. However, the makers of this drug started promoting Zofran for use to prevent NVM in women who are suffering from hyperemesis gravidarum (HG). HG is a condition whereby severe nausea and vomiting is experienced by pregnant women, in some cases requiring the expectant mom to be hospitalized so that she can get fluid and nutrition through an intravenous line (IV). The symptoms of HG usually appear between 4-6 weeks of pregnancy, and reaches its peak between 9-13 weeks. Unfortunately, in some of the worst cases up to 20% of women may need to remedy their HG for the entire duration of their pregnancy. GSK, saw an opportunity to market their drug to this particular group of women and allowed the drug to be used as an “off-label” drug for anti-nausea. The FDA never approved Zofran to be used in such a manner.
Furthermore, there have been studies conducted to verify whether or not Zofran affects a baby’s development when it comes in contact with the fetus in its peak stages of development, which is the first trimester, also the time when nausea is most likely to persist in the mom. The studies found that when Zofran is taken around this time it increases the likelihood of a baby being born with defects like cleft palate and congenital heart malformations, to name a few. Since then, there have been lawsuits filed attesting to the findings of these studies.
Stats About Infant Birth Defects In Iowa
The Iowa Department Of Health states that one in five pregnancies is affected by birth defects in the state. The Centers for Disease Control and Prevention (CDC) appraises that about one in 33 newborns is born with a birth irregularity. Zofran became widely available since 1991 and it immediately grew to be be a drug with the most written scripts in all of America. So quick was Zofran’s growth that it is understood it held 99% market share by 2005. Going by these facts our Zofran attorneys have readied possible stats of cases where newborns were affected by Zofran while also making use of averaged danger likelihoods recognized in the researches conducted by the medical community. Iowa’s population data for 2014 stands at 3,107,126. Employing this information, we calculated that there are possibly 1,556 newborn births in Iowa that were gravely affected by Zofran when they were still developing in utero during their first three months of growth.
The populations of five dominant cities in Iowa are as follows:
- Des Moines- 209,220 population
- Cedar Rapids- 129,195 population
- Davenport- 102,448 population
- Sioux City- 82,517 population
- Iowa City- 73,415 population
Possible Cases Of Cleft Palate & Congenital Heart Abnormalities In Iowa & Its Dominant Cities
Making use of the Iowa population of 3,107,126, our estimations have concluded that possible cases of cleft palate and congenital heart abnormalities are, 291 cases of cleft palate, and 1,265 cases of congenital heart abnormalities. We further calculated cases for Iowa’s dominant cities:
- Des Moines- 148 newborn birth defects with possibly 20 cleft palate, and 128 congenital heart abnormalities
- Cedar Rapids- 111 newborn birth defects with possibly 13 cleft palate, and 98 congenital heart abnormalities
- Davenport- 98 newborn birth defects with possibly 10 cleft palate, and 88 congenital heart abnormalities
- Sioux City- 89 newborn birth defects with possibly 8 cleft palate, and 81 congenital heart abnormalities
- Iowa City- 84 newborn birth defects with possibly 6 cleft palate, and 78 congenital heart abnormalities
What Have Been The Stated Birth Defects Linked To Zofran?
Zofran cases that have been brought to our attention have seen litigants state that Zofran caused birth irregularities in their newborn as a result of the mom taking the drug in the first three months of pregnancy. These claims are based on various medical studies that have been conducted all over the world. GSK still does not acknowledge that their drug causes birth defects. Nevertheless, the lawsuits have not stopped coming in and some of them have stated that Zofran caused some of the following birth irregularities:
- Hole in the heart
- Renal Malformations
- Cleft Palate
- Cleft Lip
- Webbed Toes
- Low set ears
- Club foot
Iowa Parents Looking To File A Case
ZofranLegal.com is supported by the law firms of Monheit Law, Janet Jenner & Suggs, Grant Eisenhofer, Markhoff & Mittman, and Banville Law. This website is purposed to provide timely and relevant information about the Zofran lawsuit. Although our Zofran advocates are not permitted to practice law in Iowa, we are permitted to practice law in Delaware and we also have offices in that state too. Delaware is a paramount state as that is where Zofran manufacturers are located. This means we can file and represent your case if filed in Delaware.
To date we have been contacted by multiple families from Iowa who are of the understanding that their child’s birth defect was brought on as a result of Zofran consumption during the early stages of fetal development. When you contact us we carefully evaluate your case and determine the best form of filing. We may recommend you file your case in Delaware, or at another applicable location, or we may realize that your case is better suited to be filed in Iowa with our trusted local Iowa counsel.
At this time we are aware that you may have a lot questions that need to be answered and we are here to help you with those questions. Please call us at any time, our Zofran attorneys are ready to speak with you. Meet our Zofran team here.